MATINAS BIOPHARMA HOLDINGS I (MTNB)
US5768101058 - Common Stock
We assign a fundamental rating of 2 out of 10 to MTNB. MTNB was compared to 588 industry peers in the Biotechnology industry. MTNB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, MTNB is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year MTNB has reported negative net income.
In the past year MTNB has reported a negative cash flow from operations.
In the past 5 years MTNB always reported negative net income.
MTNB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -91.39%, MTNB is doing worse than 74.66% of the companies in the same industry.
Looking at the Return On Equity, with a value of -119.20%, MTNB is in line with its industry, outperforming 41.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -91.39% | ||
| ROE | -119.2% | ||
| ROIC | N/A |
ROA(3y)-58.95%
ROA(5y)-51.01%
ROE(3y)-73.87%
ROE(5y)-62.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MTNB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MTNB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MTNB has about the same amount of shares outstanding.
The number of shares outstanding for MTNB has been increased compared to 5 years ago.
The debt/assets ratio for MTNB is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -7.59, we must say that MTNB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.59, MTNB is doing worse than 71.23% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that MTNB is not too dependend on debt financing.
MTNB has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: MTNB outperforms 49.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.59 |
ROIC/WACCN/A
WACC9.34%
2.3 Liquidity
MTNB has a Current Ratio of 5.93. This indicates that MTNB is financially healthy and has no problem in meeting its short term obligations.
MTNB has a better Current ratio (5.93) than 62.16% of its industry peers.
MTNB has a Quick Ratio of 5.93. This indicates that MTNB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.93, MTNB is in the better half of the industry, outperforming 62.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.93 | ||
| Quick Ratio | 5.93 |
3. Growth
3.1 Past
The earnings per share for MTNB have decreased by 0.00% in the last year.
The Revenue for MTNB has decreased by -65.62% in the past year. This is quite bad
Measured over the past years, MTNB shows a very strong growth in Revenue. The Revenue has been growing by 55.71% on average per year.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q0%
Revenue 1Y (TTM)-65.62%
Revenue growth 3Y90.58%
Revenue growth 5Y55.71%
Revenue growth Q2Q-100%
3.2 Future
Based on estimates for the next years, MTNB will show a very strong growth in Earnings Per Share. The EPS will grow by 23.96% on average per year.
The Revenue is expected to grow by 131.70% on average over the next years. This is a very strong growth
EPS Next Y-11.27%
EPS Next 2Y3.57%
EPS Next 3Y5.24%
EPS Next 5Y23.96%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y131.7%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MTNB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTNB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.57%
EPS Next 3Y5.24%
5. Dividend
5.1 Amount
MTNB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MATINAS BIOPHARMA HOLDINGS I
NYSEARCA:MTNB (4/26/2024, 7:05:21 PM)
After market: 0.1793 +0 (+0.22%)0.1789
0 (-1.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap44.87M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -91.39% | ||
| ROE | -119.2% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.93 | ||
| Quick Ratio | 5.93 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-11.27%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-65.62%
Revenue growth 3Y90.58%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y